Verrica Pharmaceuticals Inc. has announced the initiation of a global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of common warts. The first patient was dosed in December 2025. The Phase 3 trial follows positive results from the Phase 2 COVE-1 study, in which 51% of subjects in one cohort achieved complete clearance of all treatable warts at Day 84. Adverse events were primarily local cutaneous reactions, with no serious adverse events reported. The results of the Phase 3 trial have not yet been presented and will be available in the future. Verrica holds global rights to YCANTH for all indications outside of Japan, and the company estimates that common warts represent a multibillion-dollar market opportunity due to the lack of FDA-approved prescription therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621150-en) on January 07, 2026, and is solely responsible for the information contained therein.